Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.
<h4>Objective</h4>To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients.<h4>Method...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0237739 |
id |
doaj-01c0f7a1f1594b7b929ba67169cd5166 |
---|---|
record_format |
Article |
spelling |
doaj-01c0f7a1f1594b7b929ba67169cd51662021-03-04T11:14:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01158e023773910.1371/journal.pone.0237739Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.Silvana Di YacovoMaria SaumoyJosé Luís Sánchez-QuesadaAntonio NavarroDmitri SviridovManuel JavaloyasRamon VilaAnton VernetHann LowJudith PeñafielBenito GarcíaJordi Ordoñez-LlanosDaniel Podzamczer<h4>Objective</h4>To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients.<h4>Methods</h4>We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time.<h4>Results</h4>The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30-43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values.<h4>Conclusions</h4>In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness.https://doi.org/10.1371/journal.pone.0237739 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Silvana Di Yacovo Maria Saumoy José Luís Sánchez-Quesada Antonio Navarro Dmitri Sviridov Manuel Javaloyas Ramon Vila Anton Vernet Hann Low Judith Peñafiel Benito García Jordi Ordoñez-Llanos Daniel Podzamczer |
spellingShingle |
Silvana Di Yacovo Maria Saumoy José Luís Sánchez-Quesada Antonio Navarro Dmitri Sviridov Manuel Javaloyas Ramon Vila Anton Vernet Hann Low Judith Peñafiel Benito García Jordi Ordoñez-Llanos Daniel Podzamczer Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. PLoS ONE |
author_facet |
Silvana Di Yacovo Maria Saumoy José Luís Sánchez-Quesada Antonio Navarro Dmitri Sviridov Manuel Javaloyas Ramon Vila Anton Vernet Hann Low Judith Peñafiel Benito García Jordi Ordoñez-Llanos Daniel Podzamczer |
author_sort |
Silvana Di Yacovo |
title |
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. |
title_short |
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. |
title_full |
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. |
title_fullStr |
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. |
title_full_unstemmed |
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. |
title_sort |
lipids, biomarkers, and subclinical atherosclerosis in treatment-naive hiv patients starting or not starting antiretroviral therapy: comparison with a healthy control group in a 2-year prospective study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
<h4>Objective</h4>To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients.<h4>Methods</h4>We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time.<h4>Results</h4>The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30-43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values.<h4>Conclusions</h4>In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness. |
url |
https://doi.org/10.1371/journal.pone.0237739 |
work_keys_str_mv |
AT silvanadiyacovo lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT mariasaumoy lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT joseluissanchezquesada lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT antonionavarro lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT dmitrisviridov lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT manueljavaloyas lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT ramonvila lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT antonvernet lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT hannlow lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT judithpenafiel lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT benitogarcia lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT jordiordonezllanos lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT danielpodzamczer lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy |
_version_ |
1714804227258187776 |